



Meeting 2021

March, 11th – March, 12th

Munich, Germany



Organizing Committee:

Irene Schmid, Kristina Becker
Beate Häberle, Rebecca Maxwell
Julia von Frowein, Roland Kappler

Conference Secretary:

Department of Pediatric Surgery
Dr. von Hauner Children's Hospital
E-Mail: roland.kappler@med.uni-muenchen.de

Thursday, March 11th 2021



This is a reporting session without questions

11.00 – 13.40 **Session 1: Updates**
Chairs: **S. Branchereau, Bicêtre, France**
B. Morland, Birmingham, UK

11.00 – 11.10 **Opening Remarks**
I. Schmid, Munich, Germany
S. Branchereau, Bicêtre, France

11.10 – 11.30 **PHITT Europe / ChiLTERN WP2**
B. Morland, Birmingham, UK

11.30 – 11.50 **PHITT JCCG**
E. Hiyama, Hiroshima, Japan

11.50 – 12.10 **PHITT COG**
G. Tiao, Cincinnati, USA

12.10 – 12.20 **ChiLTERN WP1 / WP7**
K. Wheatley, Birmingham, UK

12.20 – 12.30 **ChiLTERN WP3**
C. Armengol, Badalona, Spain

12.30 – 13.00 **Lunch Break**

13.00 – 13.10 **CHIC, ChiLTERN WP4**
B. Häberle, Munich, Germany

13.10 – 13.20 **ChiLTERN WP5**
S. Warmann, Tübingen, Germany

13.20 – 13.30 **ChiLTERN WP6**
G. Veal, Newcastle, UK

13.30 – 13.40 **The redo of the SIOPEL website**
V. Weeda, Amsterdam, Netherlands

13.40 – 14.00 **Coffee Break**

Thursday, March 11th 2021



*All speakers have 12min. talk + 3min. questions via chat
All abstracts have 8min. talk + 2min. questions via chat*

14.00 – 16.10 **Session 2: Biology / Genetics**

Chairs: R. Kappler, Munich, Germany
C. Armengol, Badalona, Spain

- | | |
|---------------|---|
| 14.00 – 14.20 | Keynote lecture
The biology of childhood liver cancer – the story so far
<i>R. Kappler, Munich, Germany</i> |
| 14.20 – 14.35 | Molecular landscape of hepatoblastoma and transitional liver cell tumor
<i>E. Hiyama, Hiroshima, Japan</i> |
| 14.35 – 14.50 | Towards molecular risk stratification of HB
<i>C. Armengol, Badalona, Spain</i> |
| 14.50 – 15.05 | Molecular heterogeneity and cisplatin-resistant evolution in pediatric liver cancer
<i>T. Hirsch, Paris, France</i> |
| 15.05 – 15.20 | Molecular features of high-risk HBs and HCCs
<i>P. Sumazin, Houston, USA</i> |
| 15.20 – 15.30 | <u>Abstract:</u> Targeting Lipid Metabolism in Pediatric Liver Cancer: Statins and PCSK9 inhibitors as potential anti-tumoral drugs
<i>M. Alannan, Bordeaux, France</i> |
| 15.30 – 15.40 | <u>Abstract:</u> LHX2 suppresses hallmarks of hepatoblastoma by inactivating MAPK/ERK and Wnt/β-catenin
<i>N. Mosca, Bordeaux, France</i> |
| 15.40 – 16.10 | Panel discussion – next steps |
| 16.10 – 16.30 | Coffee Break |

Thursday, March 11th 2021



All speakers have 12min. talk + 3min. questions via chat

All abstracts have 8min. talk + 2min. questions via chat

16.30 – 18.30 **Session 3: Relapse / Resistance**

Chairs: M. Ansari, Geneva, Switzerland

J. Geller, Cincinnati, USA

16.30 – 16.50 **Keynote lecture**
Relapse and resistance – the story so far
A. O'Neill, Boston, USA

16.50 – 17.05 **Cisplatin and ICE as salvage therapy for relapsed/
refractory HB**
K. Somers, Cincinnati, USA
J. Geller, Cincinnati, USA

17.05 – 17.20 **RELIVE – the relapse HB/HCC registry**
M. Ansari, Geneva, Switzerland

17.20 – 17.35 **Glypican-3-specific CAR T cells**
A. Heczey, Houston, USA

17.35 – 17.50 **Relapse-prone unresectable HB - potential for
immunotherapy**
R. Sindhi, Pittsburgh, USA

17.50 – 18.00 **Abstract: Refractory and recurrent hepatoblastoma:
epidemiology, current treatments and outcome: the
French experience**
S. Vermeulen, Nantes, France

18.00 – 18.30 **Panel discussion – next steps**

Friday, March 12th 2021



All speakers have 12min. talk + 3min. questions via chat

All abstracts have 8min. talk + 2min. questions via chat

11.00 – 12.55 **Session 4: Pathology / Tumor models**

Chairs: R. de Krijger, Utrecht, Netherlands

C. Vokuhl, Bonn, Germany

11.00 – 11.20 **Keynote lecture**
Classification of childhood liver cancers – the story so far
R. de Krijger, Utrecht, Netherlands

11.20 – 11.35 **Not only HCC and hepatoblastoma: be aware of other malignant liver tumors in children**
C. Vokuhl, Bonn, Germany

11.35 – 11.50 **The pathology ATLAS**
R. Alaggio, Rome, Italy
S. Ranganathan, Cincinnati, USA

11.50 – 12.05 **Preclinical drug testing platform**
S. Cairo, Evry, France

12.05 – 12.15 **Abstract: Characterizing vascular invasion in hepatoblastoma**
S.A. Vasudevan, Houston, USA

12.15 – 12.25 **Abstract: Bringing the preclinical drug testing platform to the next level**
S. Demir, Munich, Germany

12.25 – 12.55 **Panel discussion – next steps**

12.55 – 13.30 **Lunch Break**

Friday, March 12th 2021



*All speakers have 12min. talk + 3min. questions via chat
All abstracts have 8min. talk + 2min. questions via chat*

13.30 – 15.30 **Session 5: Hepatocellular Carcinoma**

Chairs: A. O'Neill, Boston, USA

A. Rangaswami, San Francisco, USA

13.30 – 13.50 **Keynote lecture**
Hepatocellular pediatric tumors – the story so far
A. Rangaswami, San Francisco, USA

13.50 – 14.05 **Omics data on HCC**
T. Pietsch, Bonn, Germany

14.05 – 14.20 **What to do with NOS**
L. Lopez-Terrada, Houston, USA

14.20 – 14.35 **Current treatment for adult HCC**
E. de Toni, Munich, Germany

14.35 – 14.50 **Interventional procedures in adult HCC**
J. Ricke, Munich, Germany

14.50 – 15.00 **Abstract: Establishment of organoids and patient-derived xenografts of hepatoblastoma**
J. Carrillo-Reixach, Badalona, Spain

15.00 – 15.30 **Panel discussion – next steps**

15.30 – 16.00 **Coffee Break**

Friday, March 12th 2021



All speakers have 12min. talk + 3min. questions via chat

All abstracts have 8min. talk + 2min. questions via chat

16.00 – 18.00 Prof. von Schweinitz Farewell Session

Chairs: P. Czauderna, Gdansk, Poland

B. Häberle, Munich, Germany

16.00 – 16.20 **Keynote lecture**
Surgery – the story so far
P. Czauderna, Gdansk, Poland

16.20 – 16.35 **Pulmonary metastasectomy**
T. Hishiki, Tokyo, Japan

16.35 – 16.50 **OLT versus extreme resection**
S. Warmann, Tübingen, Germany

16.50 – 17.05 **Orthotopic liver transplantation for hepatoblastoma – late effects and long term follow-up**
G. Tiao, Cincinnati, USA

17.05 – 17.20 **Long term follow up of hepatoblastoma survivors in France**
B. Fresneau, Villejuif, France

17.20 – 17.50 **Panel discussion – next steps**

17.50 – 18.00 **Closing remarks**
S. Branchereau, Bicêtre, France
I. Schmid, Munich, Germany